Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17165346 | 0.76 | PIK3CA (0.44) | HDAC1HDAC2NPC1RAB9APIK3CA | |
| SCHEMBL31258318 | 0.76 | PIK3CA (0.44) | HDAC1HDAC2NPC1RAB9APIK3CA | |
| SCHEMBL16146528 | 0.75 | GDA (0.55) | NPC1RAB9APIK3CAMTORXDH | |
| SCHEMBL3298684 | 0.73 | BRD4 (0.56) | HDAC1HDAC2NPC1RAB9AEPHX1 | |
| SCHEMBL16145763 | 0.70 | CYP1A2 (0.62) | HDAC1HDAC2XDHCYP1A2CYP3A4 | |
| SCHEMBL3134186 | 0.69 | HDAC1 (0.43) | HDAC1HDAC2XDHPAOXGDA | |
| SCHEMBL28878261 | 0.68 | XDH (0.47) | PIK3CAMTORXDHPDE2AGDA | |
| SCHEMBL19466078 | 0.68 | NPC1 (0.54) | HDAC1HDAC2NPC1RAB9ACYP1A2 | |
| SCHEMBL20565 | 0.67 | XDH (0.67) | PIK3CAMTORXDHPDE2AGDA | |
| SCHEMBL30523428 | 0.67 | XDH (0.67) | PIK3CAMTORXDHPDE2AGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-3268021-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | Oxeia Biopharmaceuticals, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3197482-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | Oxeia Biopharmaceuticals Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3182992-A1 | METHODS OF TREATING MILD BRAIN INJURY | Oxeia Biopharmaceuticals Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2017075535-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016144978-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| EP-1161246-B1 | USE OF CERTAIN DINUCLEOTIDETRIPHOSPHATE, CYTIDINEDIPHOSPHATE AND ADENINEDIPHOSPHATE FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR STIMULATING MUCOSAL HYDRATION | INSPIRE PHARMACEUTICALS (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1280536-A2 | METHOD FOR TREATING RETINAL DEGENERATION WITH PURINERGIC RECEPTOR AGONISTS | Inspire Pharmaceuticals, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6436910-B1 | ESPECIALLY URIDINE 5'-DIPHOSPHATE; STIMULATE MUCIN SECRETION. | INSPIRE PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020052338-A1 | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof | YERXA BENJAMIN R (US) | 2002-05-02 | — | — | US | disclosed |
| US-6331529-B1 | TREATMENT OF DRY EYE DISEASE, VAGINAL DRYNESS, RHINOSINUSITIS AND DRY MOUTH | INSPIRE PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1161246-A2 | METHOD OF PROMOTING MUCOSAL HYDRATION WITH CERTAIN URIDINE, ADENINE AND CYTIDINE DIPHOSPHATES AND ANALOGS THEREOF | Inspire Pharmaceuticals (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001087913-A2 | METHOD FOR TREATING RETINAL DEGENERATION WITH PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1133304-A2 | USE OF NUCLEOTIDES AND DINUCLEOTIDES FOR THETREATMENT OF VAGINAL DRYNESS AND VULVAR PAIN | Inspire Pharmaceuticals, Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000050024-A2 | METHOD OF PROMOTING MUCOSAL HYDRATION WITH CERTAIN URIDINE, ADENINE AND CYTIDINE DIPHOSPHATES AND ANALOGS THEREOF | INSPIRE PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000030629-A2 | METHOD OF PROMOTING CERVICAL AND VAGINAL SECRETIONS | INSPIRE PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | ATP6V1B2, FABP7, GHSR | HDAC1 391/4885HDAC2 695/4885NPC1 2112/4885 |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | FABP7, PYGB, ATP6V1B2 | HDAC1 258/4885HDAC2 469/4885NPC1 965/4885 |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | HTT, SNCA, NLN | HDAC1 1091/4885HDAC2 1312/4885NPC1 221/4885 |
| US-20180071367-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENTS OR DYSFUNCTION | CRH, PYGB, CHAT | HDAC1 1590/4885HDAC2 1476/4885NPC1 2854/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | HDAC1 188/4885HDAC2 264/4885NPC1 967/4885 |
| US-20020052338-A1 | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof | NUDT1, UMPS, ADORA2A | HDAC1 4869/4885HDAC2 4879/4885NPC1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.